Racial Differences Among High-Risk Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndromes (Results from the SYNERGY Trial) - 15/08/11
, Anindita Banerjee, MS b, Karen S. Pieper, MS a, Amanda Stebbins, MS a, Alexandra Lansky, MD e, Mauricio G. Cohen, MD c, Eric Velazquez, MD a, Renato Santos, MD d, L. Kristin Newby, MD a, Enrique P. Gurfinkel, MD g, Luigi Biasucci, MD h, James J. Ferguson, MD f, Robert M. Califf, MD aRiassunto |
Management and outcomes of patients with acute coronary syndromes (ACSs) may vary according to patient race and ethnicity. To assess racial differences in presentation and outcome in high-risk North American patients with non–ST-segment elevation (NSTE) ACS, we analyzed baseline racial/ethnic differences and all-cause death or nonfatal myocardial infarction (MI) in 6,077 white, 586 African-American, and 344 Hispanic patients through 30-day, 6-month, and 1-year follow-up. Frequencies of hypertension were 66% for whites, 83% for African-Americans, and 78% for Hispanics (overall p <0.001). Use of angiography was similar across groups. Use of percutaneous coronary intervention (46% for whites, 41% for African-Americans, and 45% for Hispanics, overall p = 0.046) and coronary artery bypass grafting (20% for whites, 16% for African-Americans, and 22% for Hispanics, overall p = 0.044) differed. African-American patients had significantly fewer diseased vessels compared with white patients (p = 0.0001). Thirty-day death or MI was 14% for whites, 10% for African-Americans, and 14% for Hispanics (overall p = 0.034). After adjustment for baseline variables, African-American patients had lower 30-day death or MI compared with white patients (odds ratio 0.73, 95% confidence interval 0.55 to 0.98). There were no differences in 6-month death or MI across racial/ethnic groups. In conclusion, baseline clinical characteristics differed across North American racial/ethnic groups in the SYNERGY trial. African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| The SYNERGY trial was funded by Aventis Pharmaceuticals, Inc., Bridgewater, New Jersey, a member of the sanofi-aventis Group. Drs. Mahaffey, Lansky, Biasucci, Ferguson, and Califf were supported by sanofi-aventis. Ms. Banerjee, Ms. Pieper, and Ms. Stebbins were supported by sanofi-aventis through Duke Clinical Research Institute. |
Vol 99 - N° 3
P. 315-321 - febbraio 2007 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
